JO3197B1 - (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان - Google Patents

(مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان

Info

Publication number
JO3197B1
JO3197B1 JOP/2010/0107A JOP20100107A JO3197B1 JO 3197 B1 JO3197 B1 JO 3197B1 JO P20100107 A JOP20100107 A JO P20100107A JO 3197 B1 JO3197 B1 JO 3197B1
Authority
JO
Jordan
Prior art keywords
diazepin
ribofuranosyl
deoxy
tetrahydro
derivatives
Prior art date
Application number
JOP/2010/0107A
Other languages
English (en)
Inventor
Duvall Bridget
Hamilton Gregory
Ferraris Dana
Belyakov Sergei
Vaal Mark
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3197B1 publication Critical patent/JO3197B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

.يتم في الطلب الحالي تقديم المركبات المستخدمة لتثبيط انزيم نزع المجموعة الأمينية المسئول عن تثبيط نشاط المركبات العلاجية , وطرق استخدامها.
JOP/2010/0107A 2009-04-06 2010-04-06 (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان JO3197B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16711209P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
JO3197B1 true JO3197B1 (ar) 2018-03-08

Family

ID=42126083

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0107A JO3197B1 (ar) 2009-04-06 2010-04-06 (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان

Country Status (10)

Country Link
US (1) US8324180B2 (ar)
EP (1) EP2417146B1 (ar)
JP (1) JP5687687B2 (ar)
AR (1) AR076262A1 (ar)
AU (2) AU2010234637B2 (ar)
CA (1) CA2757743C (ar)
ES (1) ES2593088T3 (ar)
JO (1) JO3197B1 (ar)
TW (1) TWI477508B (ar)
WO (1) WO2010118006A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2778B1 (ar) 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
ES2956840T3 (es) * 2013-08-19 2023-12-29 Taris Biomedical Llc Dispositivos de administración de fármacos de múltiples unidades

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (en) * 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
EP0641352B1 (en) * 1993-02-23 1997-06-04 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
TW466112B (en) 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
PT1115391E (pt) 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
ES2273672T3 (es) 1999-03-01 2007-05-16 Halogenetics, Inc. Uso de composiciones que comprenden cldc como radiosensibilizadores en el tratamiento de enfermedades neoplasticas.
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh) * 2000-11-29 2014-01-29 三井化学株式会社 L-核酸衍生物及其合成方法
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
EP2322534A1 (en) 2001-05-18 2011-05-18 Rakesh Kumar Antiviral nucleosides
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
US20060173174A1 (en) 2004-12-08 2006-08-03 Anne-Ruth Born Difluoronucleosides and process for preparation thereof
US20080080163A1 (en) 2006-09-29 2008-04-03 Grote Industries, Inc. Illuminated devices utilizing light active sheet material with integrated light emitting diode (LED), methods of producing illuminated devices, and kits therefor
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (ar) * 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer

Also Published As

Publication number Publication date
AU2016213881B2 (en) 2018-03-22
TWI477508B (zh) 2015-03-21
AU2010234637B2 (en) 2016-05-12
CA2757743A1 (en) 2010-10-14
EP2417146A1 (en) 2012-02-15
EP2417146B1 (en) 2016-07-13
AR076262A1 (es) 2011-06-01
WO2010118006A1 (en) 2010-10-14
JP5687687B2 (ja) 2015-03-18
CA2757743C (en) 2017-10-10
TW201102397A (en) 2011-01-16
US8324180B2 (en) 2012-12-04
AU2016213881A1 (en) 2016-09-01
AU2010234637A1 (en) 2011-11-10
JP2012522840A (ja) 2012-09-27
US20100279966A1 (en) 2010-11-04
ES2593088T3 (es) 2016-12-05

Similar Documents

Publication Publication Date Title
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
SG10201811480WA (en) Therapeutic compounds and compositions
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
UA106367C2 (uk) Похідні азадиспіро[3.0.4.1]декану та їх застосування
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009012623A (es) Moduladores de cinasa heterociclicos.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
PL2231636T3 (pl) Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin
MX2011007930A (es) Conjugados de insulina cristalina.
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
UA98629C2 (ru) Соединения и способ модуляции киназ
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
JO3134B1 (ar) مثبطات نشاط akt
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
MY152062A (en) Indole derivatives as crth2 receptor antagonists
TNSN08400A1 (en) Organic compounds and their uses
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
ZA201000314B (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.